Venclexta (Venetoclax): Uses, Dosage, and Side Effects

Venclexta (venetoclax) is a targeted therapy designed to manage specific types of cancer by addressing the underlying biology of cancer cells. This medication offers a distinct approach compared to traditional chemotherapy, focusing on particular proteins that contribute to cancer cell survival.

What is Venclexta Used For?

Venclexta is a prescription oral tablet containing the active ingredient venetoclax. It belongs to a class of drugs known as B-cell lymphoma-2 (BCL-2) inhibitors. Unlike conventional chemotherapy, which broadly targets rapidly dividing cells, Venclexta specifically targets a protein crucial for cancer cell survival.

Approved for use in adults, Venclexta treats:

• Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): These conditions involve the overproduction of abnormal lymphocytes. Venclexta can be used as a primary treatment or following other therapies, often in combination with a BTK inhibitor.
• Acute Myeloid Leukemia (AML): For newly diagnosed AML, Venclexta is used in combination with chemotherapy medications. This combination is typically prescribed for adults aged 75 or older, or those with other health conditions that make intensive chemotherapy too challenging.

How Venclexta Works

Venclexta functions by targeting the specific biological processes that enable cancer cells to survive longer than they should. In many blood cancers, cells produce excessive amounts of the BCL-2 protein. This protein plays a vital role in regulating cell life cycles by blocking apoptosis, which is natural, programmed cell death. When BCL-2 levels are elevated, cancer cells continue to live and multiply, leading to an accumulation of cancer cells that can crowd out healthy blood cells.

Venclexta is designed to bind directly to the BCL-2 protein, inhibiting its function. By blocking this protein, Venclexta allows the natural process of cell death to resume, leading to the elimination of cancer cells from the body. This mechanism helps restore the balance of cells in the bone marrow, potentially enabling the return of healthy blood cell production.

Potential Side Effects of Venclexta

While Venclexta is a targeted therapy, it can still affect healthy cells and cause side effects. Most side effects can be managed with medical guidance.

Common Side Effects

Clinical trials have reported mild to moderate symptoms as individuals adjust to the therapy. These may include:

• Digestive issues, such as nausea, diarrhea, or upset stomach
• Fatigue
• Low white blood cell count (leukopenia), which can increase infection risk

Serious Side Effects

Several serious side effects require careful monitoring:

• Tumor Lysis Syndrome (TLS): This is most common at the beginning of treatment when a large number of cancer cells rapidly die. This process releases substances like uric acid, potassium, and phosphorus into the blood. If these levels rise too quickly, they can overwhelm the kidneys, potentially leading to kidney failure or dangerous heart rhythm problems.
• Serious Infections: The medication can significantly lower white blood cell counts, increasing the risk of serious infections. It is crucial to stay current on vaccinations and report any signs of fever or illness to a doctor immediately.
• Thrombocytopenia (Low Platelet Count): Platelets are essential for blood clotting. A low platelet count can lead to easier bruising or prolonged bleeding from minor cuts.
• Secondary Cancers: A small number of individuals in clinical studies developed a different type of cancer, such as skin cancer, during treatment.

Seek immediate medical attention if experiencing symptoms of a severe side effect, such as sudden confusion, unusually dark urine, heart palpitations, severe nausea, or seizures.

Venclexta Dosage and Administration

Venclexta is available as an oral tablet in strengths of 10 mg, 50 mg, and 100 mg. Due to its ability to rapidly break down cancer cells, Venclexta is introduced slowly to mitigate the risk of side effects. This gradual dosage increase is known as the “ramp-up phase.”

• For CLL and SLL: The typical ramp-up phase lasts approximately 5 weeks. Treatment usually begins with a very low dose, which is increased weekly as the body adapts. The standard daily maintenance dose is 400 mg.
• For AML: The ramp-up phase for AML treatment is shorter, typically occurring over the first 3 to 4 days of the initial treatment cycle. The recommended dosage for AML is either 400 mg or 600 mg, depending on co-administered medications.

Side Effect Monitoring During Ramp-Up

Close monitoring is essential during the initial phase due to the heightened risk of rapid cell breakdown. Blood tests are performed before the first dose and prior to every dose increase. In many instances, laboratory results are checked within 6 to 8 hours after a dose to ensure stable creatinine and electrolyte levels.

Interactions and Precautions

Venclexta is metabolized by specific liver enzymes (CYP3A), meaning other substances that use these enzymes can influence its effectiveness.

Drug and Food Interactions

• Strong CYP3A Inhibitors: Certain antifungals, antibiotics, and HIV medications can interfere with Venclexta. Dosage adjustments or alternative medications may be necessary.
• Dietary Restrictions: Certain fruits, including grapefruit, starfruit, and Seville oranges, can block the enzymes that break down Venclexta. These should be avoided throughout treatment.
• Warfarin and Digoxin: Venclexta can increase the levels of warfarin and digoxin in the body, potentially raising the risk of serious side effects like excessive bleeding. If taking these heart medications, a doctor may advise administering them at least 6 hours before Venclexta.
• Live Vaccines: Live vaccines should not be administered immediately before, during, or after Venclexta treatment until a doctor confirms it is safe. Venclexta can weaken the immune system, potentially reducing vaccine effectiveness or causing a serious infection.

Health Conditions and Fertility

• Organ Function: Individuals with severe liver conditions may be prescribed a lower dose and require closer monitoring of kidney function due to the risk of TLS.
• Reproductive Health: Venclexta can be harmful to a developing fetus. Effective birth control is crucial during treatment and for 30 days after the final dose for individuals who can become pregnant or whose partners can. Breastfeeding should be avoided during treatment and for at least 1 week after the final dose.
• Male Fertility: Animal studies suggest a potential impact on male fertility. Discussions about fertility preservation options with a doctor are advisable for those considering starting a family.

Venclexta vs. Imbruvica

When considering treatment for CLL or SLL, Venclexta is often compared with Imbruvica (ibrutinib). Both are effective targeted therapies, but they operate differently:

• Mechanism: Venclexta targets the BCL-2 protein, promoting cancer cell death. Imbruvica, a BTK inhibitor, blocks signals that cancer cells use to grow and multiply.
• Treatment Duration: Venclexta, when combined with other drugs for CLL or SLL, is often a “fixed-duration” therapy (e.g., 12 or 24 months). When used alone, both Venclexta and Imbruvica can be taken continuously as long as they remain safe and effective.
• Safety Monitoring: Venclexta requires intensive monitoring for TLS during the initial weeks. Imbruvica may necessitate more long-term monitoring for cardiac issues like atrial fibrillation or high blood pressure.

Cost Considerations

As a specialized medication, the cost of Venclexta can vary significantly based on insurance coverage. Manufacturer patient assistance programs and copay cards are often available to help reduce out-of-pocket expenses. Patients can inquire with their pharmacy or clinic’s financial counselor for assistance with these programs.

Conclusion

Venclexta represents an effective treatment option for chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. While the initial “ramp-up” phase demands careful monitoring, many individuals find managing this oral medication at home to be a manageable part of their routine.

Patients are encouraged to discuss specific risk factors for tumor lysis syndrome, potential dosage modifications based on health conditions, frequency of blood work during the initial weeks, interactions with current medications, and the suitability of a fixed-duration versus indefinite treatment approach with their healthcare provider.